Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Roche, Garvan Institute Epigenomic Partnership

Published: Wednesday, August 20, 2014
Last Updated: Wednesday, August 20, 2014
Bookmark and Share
Roche and the Garvan Institute of Medical Research today announce a collaboration to develop new technologies for targeted epigenomic analysis using DNA sequencing.

Genomics is a rapidly evolving field with a focus on realizing the potential use of sequencing information in patient diagnosis and treatment.  More recently, epigenetics - the heritable changes in gene expression that are not caused by changes in the DNA sequence or genetic code, but rather involve secondary chemical modifications of the DNA and the structural proteins in chromosomes - is being recognized as playing an important role in a host of biological processes and their role in cancer has been increasingly investigated.  Due to the myriad of epigenomic events responsible for influencing expression of genes in chromosomes, more advanced methods are being sought to accurately analyze these changes.

Under the terms of the two-year discovery agreement, the Garvan Institute and Roche will collaborate to develop new methods to accurately analyze regions of the epigenome. The collaboration brings together the world-leading genomics expertise and infrastructure at the Garvan Institute and the best-in-class products for target enrichment from Roche NimbleGen, part of the Roche Sequencing Unit. As part of the agreement, the SeqCap Target Enrichment System from Roche will be used by scientists at the Garvan Institute to further their research in epigenetic influences on human diseases.

“This is an excellent example of collaboration between a leading edge company and research institute in the development of advanced technology for genetic analysis, which will empower more research into human biology and disease, and lead to many translational opportunities,” said Professor John Mattick, Executive Director of the Garvan Institute.

 “In addition to our recent investments in sequencing platform technologies,  our research team is  working closely with key opinion leaders to advance sequencing applications of current and future technologies,” said Tom Albert, Head of Research at Roche’s Sequencing Unit.  “This collaboration with the Garvan Institute illustrates the potential of SeqCap Target Enrichment products in additional sequencing applications for epigenetic research. This brings us closer to delivering sequencing applications to the clinic that offer truly differentiated medical value.”

Financial terms of the collaboration are not disclosed.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Roche Acquires GeneWEAVE to Strengthen Offerings in Microbiology Diagnostics
GeneWEAVE’s Smarticles technology enhances Roche’s role in fighting drug-resistant bacteria.
Friday, August 14, 2015
Roche Acquires Ariosa Diagnostics
Acquisition will see Roche enter the non-invasive prenatal test (NIPT) and cell-free DNA testing services markets.
Wednesday, December 03, 2014
Roche Receives FDA Clearance for Strep A Test
The cobas Strep A test is the first molecular point of care test to provide a result in 15 minutes for this common infection.
Friday, November 14, 2014
Roche to Invest in New Diagnostic Manufacturing Facility in China
The facility will address Asia Pacific’s growing demand for diagnostics.
Monday, November 10, 2014
Roche Invests For The Future In Its Basel Site
Investments of 3 billion Swiss francs in modern research infrastructure, attractive workplaces and sustainable site development.
Thursday, October 23, 2014
Roche Acquires Genia Technologies for up to $350M
Acquisition of the privately held Genia to strengthen Roche's next generation sequencing pipeline.
Monday, June 02, 2014
Roche Acquires IQuum
Acquisition will allow Roche to quickly enter the point of care segment of molecular diagnostics.
Monday, April 07, 2014
Roche, Discuva Collaborate
Companies join forces to combat life-threatening infections caused by multi-drug resistant bacteria.
Friday, February 28, 2014
Roche Signs Licensing Agreement with Sysmex Inostics
Under the terms of the agreement, Roche grants Sysmex a worldwide, non-exclusive, royalty-bearing license.
Friday, February 21, 2014
FDA Approves New Streamlined Workflow Option for Roche's Cobas HPV Test
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow.
Friday, June 28, 2013
Change to the Roche Corporate Executive Committee
Appointment of John C. Reed as Head of Roche Pharma Research and Early Development.
Monday, January 28, 2013
Kingston Hospital Delivers Point of Care Testing Excellence
Roche cobas® b 221 blood gas analysers and Roche POC IT connectivity bring improvements for patients and staff alike.
Tuesday, July 03, 2012
Roche and Life Technologies Corporation Sign New PCR IVD Licenses
Companies announced that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.
Thursday, February 23, 2012
Roche Enters Strategic Alliance with Technoclone to Expand Reagent Portfolio for Coagulation Diagnostics Line Targeted for US and Canada in 2014
Focus on reagents for thrombosis and cardiovascular diagnostics complements Roche plans to introduce comprehensive line of coagulation analyzers for hospital and reference labs
Wednesday, February 01, 2012
Roche Diagnostics Announces Dan Zabrowski as New Head of Roche Applied Science
He succeeds Paul Brown who has led Roche Applied Science since September 2011. Dan Zabrowski will report to Daniel O’Day, COO Roche Diagnostics.
Tuesday, January 31, 2012
Scientific News
Will Brain Palpation Soon Be Possible?
Researchers have developed non-invasive brain imaging technique which provides the same information as physical palpation.
Groundbreaking Computer Program Diagnoses Cancer in Two Days
Researchers have combined genetics with computer science and created a new diagnostic technology can with 85 per cent certainty identify the source of the disease and thus target treatment and, ultimately, improve the prognosis for the patient.
Detecting HIV Diagnostic Antibodies with DNA Nanomachines
New research may revolutionize the slow, cumbersome and expensive process of detecting the antibodies that can help with the diagnosis of infectious and auto-immune diseases such as rheumatoid arthritis and HIV.
Horse Illness Shares Signs of Human Disease
Horses with a rare nerve condition have similar signs of disease as people with conditions such as Alzheimer’s, a study has found.
Compound Doubles Up On Cancer Detection
Researchers have found that tagging a pair of markers found almost exclusively on a common brain cancer yields a cancer signal that is both more obvious and more specific to cancer.
The Age of Humans Controlling Microbes
Engineered bacteria could soon be used to detect environmental toxins, treat diseases, and sustainably produce chemicals and fuels.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Are Changes to Current Colorectal Cancer Screening Guidelines Required?
Editorial suggests more research is needed to pinpoint age to end aggressive screening.
New Molecular Marker for Killer Cells
Cell marker enables prognosis about the course of infections.
Sniffing Out Cancer
Scientists have been exploring new ways to “smell” signs of cancer by analyzing what’s in patients’ breath.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos